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A series of studies in recent years have performed culture-independent methodologies, such as 
16S rRNA gene sequencing of bacterial DNA extracted from patient clinical samples, to infer 
the microbiota of different human niches and to differentiate between health and disease. Such 
studies of respiratory samples from people with cystic fibrosis (CF), have demonstrated that 
the lower airway microbiota evolves with age including an increased bacterial richness during 
early life before progressing to a loss in bacterial community diversity and increased 
dominance by the common and historically recognised CF taxa such as Pseudomonas and 
Burkholderia.1-4 The latter features are also typical of those with the most advanced or 
progressive respiratory disease and are likely to be at least, in part, driven by antibiotic 
exposure.1 The lower airway microbiota has also been compared between disease stability and 
pulmonary exacerbations and changes in the relative abundance of taxa may be indicative of 
the onset of an exacerbation in some patients.5 Despite these important findings, it remains 
unclear how knowledge of the lower airway microbiota could be exploited in routine clinical 
practice. 
 
Given the paucity of longitudinal culture-independent studies of the CF lower airway 
microbiota and associations with clinical outcomes, the paper by Acosta and colleagues 
published in Thorax this month is timely.6 The work provides evidence that ecological indices 
calculated from the lower airway microbiota could potentially be applied as “biomarkers” to 
predict those who are at risk of early disease progression. 
 
In the study6 16S rRNA gene sequencing of biobanked sputum samples, collected 
prospectively over two decades from a cohort of 104 clinically stable young adults with CF 
(18-22 years old), was performed and related to clinical outcomes in years following sample 
collection. The primary outcome was end-stage lung disease (death or lung transplantation <25 
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years) and the secondary outcomes were accelerated absolute and relative lung function decline 
(>-3% per year FEV1) up to 5-years after the date of sputum collection. Multiple quantitative 
ecological indices (e.g. Shannon’s and Simpson’s diversity indices and Observed and Chao1 
richness estimators) were calculated from the respiratory microbiota perhaps due to a lack of 
consensus about which are most informative. Poor clinical outcomes were seen in those with 
more advanced disease at study baseline and also, lower bacterial community diversity that 
was dominated by Pseudomonas with a relative abundance of at least 50%. Overall, these 
findings corroborate with observations of prior cross-sectional studies and a longitudinal study 
of six patients followed for 8-9 years.1-4 However, an important caveat of the findings is that 
there was greater evidence of associations between the ecological indices and the primary 
outcome compared to the secondary outcomes, especially when evaluated as an absolute lung 
function decline. It is not clear why these differences exist as patients with increased risk of 
death/transplantation would also be expected to experience an enhanced loss of lung function 
over time.  
 
One of the major limitations of making comparisons of ecological measures of the lower airway 
microbiota to clinical outcomes is that significant correlations do not imply direct nor causal 
relationships. 16S rRNA gene sequencing also does not reflect dynamic interactions that might 
occur in vivo between bacteria (and other micro-organisms), and the host which may influence 
the community composition and structure, immune response and ultimately, impact on disease 
progression.7 8 Furthermore, the pathogenicity within a genus might differ between species but 
relative low taxonomic resolution of some genera by 16S rRNA gene sequencing precludes 
confident analysis to the species level. In this study6 bacterial communities with a higher 
relative abundance of Streptococcus (≥25%) were associated with less evidence of disease 
progression indicating a possible protective role of this genus. However, there have also been 
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reports that both the Streptococcus milleri group and Group A Streptococcus are implicated in 
pulmonary exacerbations, a key influencer of lung disease progression in CF.9 10 Bacteria in 
low abundance may also influence disease pathogenesis which Acosta and colleagues 
highlight.6 For example, higher levels (≥0.75%) of Granulicatella and Gemella were associated 
with less disease progression and there was some evidence of detection of Stenotrophomonas 
(<1%) and early death/lung transplantation. Granulicatella and Gemella spp. are considered 
commensal flora in the routine laboratory and Stenotrophomonas maltophilia has been 
associated with disease trajectory.11 
 
It is well recognised that advancing lung disease in CF is due to infection with Pseudomonas 
aeruginosa and as a result, eradication strategies, treatment of exacerbations and chronic 
suppression are the standard of care.12 Therefore, it is not surprising that the authors report an 
association between Pseudomonas dominance in the microbiota and early end-stage disease.6 
However, it was intriguing that this correlation was not replicated with either qualitative 
(presence/absence), phenotypic (mucoidy) or quantitative (log-level) routine culture results. 
Such culture results have been identified as potential predictors of poor outcomes by others.13 
14 A limitation of the study was that DNA from non-viable cells was not removed prior to 
sequencing. This might be important given that those with advanced disease were more likely 
to be prescribed inhaled antibiotics which could impact on cell death and may contribute to 
discrepancies between molecular and culture results. DNA from non-viable cells can be 
removed by the addition of propidium monoazide or alternatively, the viable bacterial 
community can be assessed by extended-quantitative culture.5 15 In addition, this study6 does 
not report P. aeruginosa genotypes, despite earlier studies of the “Prairie” epidemic strain 
being common in the same setting, and being associated with worse outcomes such as an 
increased risk of death or lung transplantation.16 Furthermore, the study used frozen sputum 
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samples, some of which were collected 20 years earlier.6 Studies have shown that delays in 
freezing or multiple freeze-thaw events can adversely affect the sputum microbiota, yet short-
term duration of frozen storage does not.17-19 While the current study did not determine if long-
term storage impacts on the bacterial community, quality control procedures and protocols 
were followed to optimise DNA preservation.  
 
We believe that the study by Acosta and colleagues makes an important contribution to 
knowledge of the CF lower airway microbiota and it demonstrates how a complex bacterial 
community may potentially be utilised to identify “at-risk” cohorts.6 In an attempt to simplify 
interpretation of quantitative diversity indices, patients were stratified based on pre-defined 
cut-off values which the authors identified as best discriminating between outcomes. Notably 
a Shannon diversity Index <1 was predictive of the highest risk of future negative outcomes. 
Novel biomarkers that identify those at an increased risk of worse outcomes could help inform 
clinical decision-making to limit disease progression by initiating intensification of chronic 
therapies, review of treatment adherence and optimising nutrition.  
 
There are questions that remain: 
1. Is it feasible to use biomarker testing of the lower airway microbiota? To be widely 
implemented in clinical microbiological laboratories, biomarker testing should provide rapid, 
accurate results that are easy to apply and importantly, cost-effective. Currently, preparation of 
clinical samples for 16S rRNA gene sequencing is laborious and expensive and the software 
tools and analyses require bioinformatic expertise. Furthermore, whilst providing data to 
support the use of microbiota results for potential clinical predictions, this study also 
highlighted that lung function at study baseline was an independent predictor of early death or 
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lung transplant.6 Therefore, a larger prospective cohort of patients from different CF centres 
are required to assess the accuracy of using community diversity as a biomarker. Such trials 
are possible with the Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in 
Exacerbations: Results Stratified (CFMATTERS) trial currently underway and comparing the 
use of microbiota-directed antibiotic treatment with standard therapy for pulmonary 
exacerbations (https://www.cfmatters.eu). 
 
2. When should biomarker testing of the lower airway microbiota begin? The age range of 
CF patients included in this study corresponds to those transitioning from paediatric to adult 
care, which is a significant milestone that requires careful planning.6 20 Therefore, this might 
represent the ideal opportunity to perform biomarker testing that could inform a personalised 
treatment strategy of young adults with CF at a time when clinical decline is frequently 
observed as the individual is transitioning to a more independent lifestyle.  
 
3. Does the respiratory sample type matter? Sputum was used to infer the lower airway 
microbiota in this study.6 Adolescents transitioning from paediatric to adult CF care are 
becoming progressively healthier (improved lung function and nutritional status)21 and the use 
of therapies that enhance CFTR function22 23 could mean that, in the future, collection of 
expectorated sputum might be exceptional rather than the norm. Alternative clinical samples 
such as oropharyngeal or cough swabs may not represent the lower airway microbiota. For 
example, the recent CF-Sputum Induction Trial (CF-SpIT) demonstrated that the intra-patient 
microbiota of sputum is similar to bronchoalveolar lavage but different to cough swabs.24 
Therefore, how generalisable the results of the study are to other sample types requires 
investigation. 
 
  7
In conclusion, Acosta and colleagues provide novel data on a topic that is of great interest to 
researchers and healthcare professionals alike. The use of long-term outcomes is a strength and 
the study has begun to address the knowledge gap of how the results of culture-independent 
analyses could potentially inform clinical care. Future studies of other cohorts (e.g. younger 
cohorts, older cohorts and endpoints considered beyond 25 years of age) using the same 
techniques and parameters to attempt to replicate the key findings will be important to convince 
hospital laboratories and clinicians that lower airway microbiota “biomarkers” are ready for 
implementation.  
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